Penn Medication on the AACR Annual Assembly 2023

ORLANDO – Researchers from the Abramson Most cancers Heart and Perelman College of Medication on the College of Pennsylvania will current information on the most recent advances throughout the total spectrum of most cancers analysis on the American Affiliation for Most cancers Analysis (AACR) Annual Assembly 2023 from April 14-19 in Orlando, Florida. Comply with us on Twitter @PennMDForum and @PennCancer for updates.

Knowledgeable Interviews

Specialists from the Perelman College of Medication can be found to touch upon a variety of subjects in most cancers science and drugs in the course of the assembly on website and by video name, phone or e mail. To rearrange interviews, please contact Meagan Raeke at [email protected] or 267-693-6224.

Information Releases

4 Abramson Most cancers Heart Researchers Obtain Prime AACR Awards.

Key Displays

Penn Medication researchers will current 4 plenary classes – together with remarks from the 2023 Annual Assembly Program Committee Chair Robert Vonderheide, MD, DPhil, director of the Abramson Most cancers Heart, within the opening and shutting classes – three mimisympoiums, 18 posters, and greater than two dozen invited talks. Key shows are highlighted under.

Minisymposium:

• B7-H4 is an actionable goal in treatment-resistant excessive grade serous ovarian carcinoma (Abstracts 1133)
  Analysis led by Sarah Gitto, PhD, teacher of Pathology and Laboratory Medication, and Fiona Simpkins, M.D, professor of Obstetrics and Gynecology, discovered that B7-H4 was overexpressed in 92 p.c of excessive grade serous ovarian carcinoma tumors at analysis and maintained excessive ranges even following remedy. A novel antibody-drug conjugate that targets B7-H4 confirmed sturdy anti-tumor response in pre-clinical fashions, together with these resistant to plain of care therapies. Gitto will current the findings throughout a minisymposium session on Sunday, April 16 at 3 pm ET in Room W331.
• Breast most cancers threat within the common inhabitants varies primarily based on mutation kind and site (Abstracts 1183)
  By analyzing information from greater than 30,000 breast most cancers instances and controls, a crew led by Mwangala Akamandisa, PhDa postdoctoral researcher in Translational Medication and Human Genetics, and Katherine Nathanson, M.Dthe Pearl Basser Professor for BRCA-Associated Analysis, discovered that the precise kind and site of mutations inside BRCA2 and CHEK2 genes needs to be thought-about throughout genetic counseling about breast most cancers threat. Akamandisa will current the findings throughout a minisymposium session on Sunday, April 16 at 3 pm ET in Room W304 EH.
• New perception into mechanisms of prostate most cancers cell progress (Abstracts 3444)
  Analysis led by Andrea Detlefsen, a predoctoral fellow in Techniques Pharmacology and Translational Therapeutics, and Trevor Penning, PhD, director of the Heart of Excellence in Environmental Toxicology, based a mechanism accountable for resistance to androgen receptor signaling inhibitors in major and metastatic fashions of prostate most cancers. The enzyme AKR1C3 converts DHEA-S, which performs an essential position in making testosterone, into potent androgens that drive prostate most cancers progress and remedy resistance. Detlefsen will current the findings throughout a minisymposium session on Monday, April 17 at 2:30 pm ET in Room W311 EH.

Scientific Trials in Progress and Late-Breaking Posters:

• Porcine brain-derived hydrogel carriers for intratumoral administration of mobile immunotherapies enhances anti-tumor potential in post-resection GBM (Summary LB026)
  The poster session is on Sunday, April 16 from 1:30 to five pm ET in Part 35.

• Armored bicistronic CAR T cells with dominant-negative TGF-β receptor II to alleviate antigenic heterogeneity and suppressive immune microenvironment in glioblastoma (Summary LB097)
  The poster session is on Monday, April 17 from 9 am to 12:30 pm ET in Part 35.

• An open label, dose escalation, section 1 examine of AT101, a novel CD19-directed CAR-T cell remedy focusing on a membrane-proximal epitope of CD19, in sufferers with relapsed or refractory B cell non-Hodgkin lymphoma (Summary CT130)
  The poster session is on Monday, April 17 from 1:30 to five pm ET in Part 46.

Invited Audio system on Matters of Curiosity:

• AI for Drug Discovery: Many proteins that play a key position in most cancers are thought-about tough drug targets, if not fully undruggable, as a result of an obvious lack of pockets the place small molecules can bind. That might change as synthetic intelligence makes it attainable to extra simply establish hidden or “cryptic” pockets. Gregory Bowman, PhDa professor of Biochemistry and Biophysics and Bioengineering, developed a neural community, known as PocketMiner, that discovered as much as 50 p.c of proteins considered unruggable may very well be targetable by means of cryptic pockets. Bowman will current “What if all of your favourite proteins are druggable?” in a plenary session on Wednesday, April 19 at 8 am ET in W Corridor A2-3.
• Immune Well being: Because the founding director of the Immune Well being^® challenge at Penn Medication’s Abramson Most cancers Heart, E. John Wherry, PhD, chair of Techniques Pharmacology and Translational Therapeutics, is main efforts to outline and monitor particular person “immune well being” fingerprints that may present perception for interception, analysis, and remedy for most cancers and different illnesses. With advances in information science and evaluation, immune well being is the subsequent frontier in personalised drugs. Wherry will current “Immune cells as ‘biosensors’ and the premise for immune well being profiling of most cancers and past” in an Advances in Diagnostics and Therapeutics session on Tuesday, April 18 at 12:30 pm ET within the Tangerine Ballroom 3-4 (WF3) -4).
• FLASH radiation: The way forward for radiation remedy might embrace supply of ultra-high dose charges in lower than a second to cut back radiation-induced toxicities. As FLASH radiation will get nearer to definitive medical trials in human sufferers, Constantinos Koumenis, PhDthe Richard H. Chamberlain Professor of Radiation Oncology, is main analysis to find out if this paradigm-shifting strategy can extra successfully kill tumor cells and spare wholesome tissue in only a few therapies. Koumenis will chair the Advances and Diagnostics and Therapeutics session, “FLASH Radiotherapy: From Animal Fashions to the Clinic” on Sunday, April 16 at 1 pm ET in Room W307.